Market Signal Briefing

Broadcom President and CEO Hock Tan joins 'Mad Money' host Jim Cramer to talk the recently announced deal with OpenAI, competition in the space, and more.

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline.

So what: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (2) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of Jasper's products, including briquilimab; (3) the foregoing increased the likelihood of disruptive cost-reduction measures; (4) accordingly, Jasper's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Amazon fired a Palestinian engineer who was suspended last month after he protested the company's work with the Israeli government.

Ahmed Shahrour, who worked as a software engineer in Amazon's Whole Foods business in Seattle, received an email on Monday informing him of his termination. When he was suspended in September, Amazon said the decision was the result of messages Shahrour posted on Slack criticizing the company's ties to Israel.

Amazon said its investigation found Shahrour had violated the company's standards of conduct, written communication policy and acceptable use policy, alleging that he "misused company resources, including by posting numerous non-work-related messages pertaining to the Israel-Palestine conflict."

"In the next 24hrs you will receive an email with detailed information about your termination, including information about your benefits and final pay," an Amazon human resources employee wrote in a message to Shahrour that was obtained by CNBC. "We appreciate the contributions you've made during your time with Amazon and wish you the best in your future endeavors."

An employee group associated with Shahrour put out an afternoon press release saying that he was fired after a five-week suspension "for protesting Amazon's $1.2 billion contract with the Israeli government and military, known as Project Nimbus, which he states constitutes collaboration in the ongoing genocide in Gaza."

Shahrour had urged the company to drop the contract that involves Amazon providing the Israeli government with artificial intelligence tools, data centers and other infrastructure. He also protested and handed out flyers at Amazon's downtown Seattle headquarters.

In a statement to CNBC, Shahrour said his firing is "a blatant act of retaliation designed to silence dissent from Palestinian voices within Amazon and shield Amazon's collaboration in the genocide from internal scrutiny."

watch now

Amazon spokesperson Brad Glasser told CNBC in a statement that the company doesn't tolerate "discrimination, harassment or threatening behavior or language of any kind in our workplace."

"When any conduct of that nature is reported, we investigate it and take appropriate action based on our findings," Glasser said.

Shahrour's termination comes on the same day that Palestinian militant group Hamas released the first seven surviving Israeli hostages, marking the first stage of a ceasefire deal brokered with the help of U.S. President Donald Trump. As part of the agreement, Israel was also scheduled to free nearly 2,000 Palestinian detainees and prisoners later in the day.

The war started just over two years ago, when Hamas-led militants attacked southern Israel on Oct. 7, 2023, killing roughly 1,200 people and taking hundreds of hostages. Israel followed with a sustained assault that killed more than 67,000 Palestinians, including thousands of civilians, according to Gaza's Health Ministry.

Across the tech industry, workers have become more outspoken in their criticism of business dealings with the Israeli military.

On Thursday, a Microsoft engineer resigned after 13 years at the software giant, claiming the company continues to sell cloud services to the Israeli military and that executives won't discuss the war in Gaza. Scott Sutfin-Glowski, a principal software engineer, informed colleagues in a letter that, "I can no longer accept enabling what may be the worst atrocities of our time."

In the letter, he referred to a February Associated Press article that said Israel's military had at least 635 Microsoft subscriptions, and he claimed the vast majority of them remain active.

Microsoft fired two employees in August who participated in a protest inside the company's headquarters. In April 2024, Google terminated 28 employees after a series of protests against labor conditions and its involvement in Project Nimbus.

Amazon hasn't acknowledged the Nimbus contract beyond stating that it provides technology to customers "wherever they are located." Google has previously said it provides generally available cloud computing services to the Israeli government that aren't "directed at highly sensitive, classified or military workloads." Microsoft said in August that most of its work with Israel Defense Forces involves cybersecurity for the country, and that the company intends to provide technology in an ethical way.

— CNBC's Jordan Novet contributed to this report.

watch now

ADELAIDE, AU / ACCESS Newswire / October 13, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) advises that the attached presentation has been presented today at the Australian Gold Conference. A copy of this presentation can be accessed on the ASX website, the investor section of Barton's website, or directly by clicking here.

VALHALLA, N.Y.--(BUSINESS WIRE)--FUJIFILM North America Corporation, Imaging Division, today announced the addition of instax AiR Studio™ and Click to Collage features to its instax mini Link™ for Nintendo Switch App1. The free, downloadable app will be compatible with all instax mini Link™ smartphone printers as well as Nintendo Switch and Nintendo Switch 2. With the App, users can share their favorite character moments with fellow gamers by printing a custom, one-of-a-kind instax™ mini photo2.

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 14,864,865 shares of its common stock at a price to the public of $18.50 per share. The gross proceeds to the Company from this offering are expected to be approximately $275.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 2,229,729 shares of the Company's common stock at the public offering price, less the underwriting discount.

The offering is expected to close on or about October 15, 2025, subject to satisfaction of customary closing conditions. Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated are acting as the joint book-running managers for the offering. Wedbush Securities Inc. is acting as lead manager for the offering.

A registration statement on Form S-3 (File No. 333-285341) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on March 7, 2025. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be  filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected];  Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at [email protected] or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, telephone: (415) 364‐2720 or by emailing [email protected] final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

Safe Harbor / Forward Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding Spyre’s expectations regarding the consummation of the offering and the satisfaction of customary closing conditions with respect to the offering. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect,” the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, the anticipated timing of the offering, market conditions and satisfaction of customary closing conditions related to the offering, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s clinical trial design, interpretation of data and the Company’s ongoing or planned clinical trials for the Company’s product candidates, including the Company’s planned SKYWAY-RD Phase 2 clinical trial design and the Company’s plans for and timing of cohort initiation for combination arms for the ongoing SKYLINE-UC Phase 2 platform trial across different jurisdictions; the potential for final clinical data not being consistent with or different than the previously disclosed data for the Company’s programs; the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on the Company’s operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact the Company’s business operations, including restricting international trade by the United States, China or other countries and the BIOSECURE Act or similar act if passed into law; and those risks described in the Company’s most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q, as well as in other filings and reports that the Company makes from time to time with the SEC. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for the Company’s management to predict all risks, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. The Company undertakes no obligation to update publicly any forward-looking statement for any reason after the date of this press release to conform these statements to actual results, to reflect changes in the Company's expectations, or otherwise, except as required by law.

For Investors: 
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
[email protected] 

For Media: 
Josie Butler, 1AB
[email protected] 

TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by TIME as one of the “Best Inventions of 2025” in the Medical and Healthcare category.

TIME’s annual list of the Best Inventions features 300 extraordinary innovations changing lives. To compile the 2025 list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields such as health care and AI. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact. For more information, please visit
time.com/collections/best-inventions-2025/.

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and their care partners continue to slow disease progression following the 18-month initial treatment period. The treatment was approved in the U.S. in August 2025 and launched on October 6. LEQEMBI IQLIK offers patients and their care partners the potential to shorten administration time (approximate injection time of 15 seconds), providing an option to continue treatment without having to worry about visiting an infusion center. Moreover, it has the potential to reduce healthcare resources associated with intravenous (IV) maintenance dosing, such as preparation for infusion and nurse monitoring, while increasing infusion capacity for new eligible patients to begin initiation treatment and streamlining the overall AD treatment pathway.

LEQEMBI, recognized as one of TIME’s “Best Inventions of 2023,” is the first approved anti-amyloid treatment for AD shown to slow disease progression and cognitive and functional decline in adults with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). LEQEMBI has been approved in 50 countries and is under regulatory review in 10 countries. In early September, Eisai initiated a rolling Supplemental Biologics License Application (sBLA) to the U.S. FDA for LEQEMBI IQLIK as a subcutaneous starting dose for the treatment of early AD under Fast Track Status.

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

INDICATION

LEQEMBI® is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

IMPORTANT SAFETY INFORMATION

WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause ARIA, characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events, including seizure and status epilepticus, can occur. ARIA can be fatal. Serious intracerebral hemorrhages (ICH) >1 cm, some of which have been fatal, have been observed with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy to a patient being treated with LEQEMBI. Apolipoprotein E ε4 (ApoE ε4) Homozygotes: Patients who are ApoE ε4 homozygotes (~15% of patients with AD) treated with this class of medications have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed, they can still be treated with LEQEMBI; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA. Consider the benefit of LEQEMBI for the treatment of AD and the potential risk of serious ARIA events when deciding to initiate treatment with LEQEMBI. CONTRAINDICATION

Contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. Reactions have included angioedema and anaphylaxis.

WARNINGS AND PRECAUTIONS

AMYLOID-RELATED IMAGING ABNORMALITIES

Medications in this class, including LEQEMBI, can cause ARIA-E, which can be observed on MRI as brain edema or sulcal effusions, and ARIA-H, which includes microhemorrhage and superficial siderosis. ARIA can occur spontaneously in patients with AD, particularly in patients with MRI findings suggestive of cerebral amyloid angiopathy (CAA), such as pretreatment microhemorrhage or superficial siderosis. ARIA-H generally occurs with ARIA-E. Reported ARIA symptoms may include headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms usually resolve over time.

Incidence of ARIA
Symptomatic ARIA occurred in 3% and serious ARIA symptoms in 0.7% with LEQEMBI. Clinical ARIA symptoms resolved in 79% of patients during the period of observation. ARIA, including asymptomatic radiographic events, was observed: LEQEMBI, 21%; placebo, 9%. ARIA-E was observed: LEQEMBI, 13%; placebo, 2%. ARIA-H was observed: LEQEMBI, 17%; placebo, 9%. No increase in isolated ARIA-H was observed for LEQEMBI vs placebo.

Incidence of ICH
ICH >1 cm in diameter was reported in 0.7% with LEQEMBI vs 0.1% with placebo. Fatal events of ICH in patients taking LEQEMBI have been observed.

Risk Factors of ARIA and ICH
ApoE ε4 Carrier Status
Of the patients taking LEQEMBI, 16% were ApoE ε4 homozygotes, 53% were heterozygotes, and 31% were noncarriers. With LEQEMBI, ARIA was higher in ApoE ε4 homozygotes (LEQEMBI: 45%; placebo: 22%) than in heterozygotes (LEQEMBI: 19%; placebo: 9%) and noncarriers (LEQEMBI: 13%; placebo: 4%). Symptomatic ARIA-E occurred in 9% of ApoE ε4 homozygotes vs 2% of heterozygotes and 1% of noncarriers. Serious ARIA events occurred in 3% of ApoE ε4 homozygotes and in ~1% of heterozygotes and noncarriers. The recommendations on management of ARIA do not differ between ApoE ε4 carriers and noncarriers.

Radiographic Findings of CAA
Neuroimaging findings that may indicate CAA include evidence of prior ICH, cerebral microhemorrhage, and cortical superficial siderosis. CAA has an increased risk for ICH. The presence of an ApoE ε4 allele is also associated with CAA.

The baseline presence of at least 2 microhemorrhages or the presence of at least 1 area of superficial siderosis on MRI, which may be suggestive of CAA, have been identified as risk factors for ARIA. Patients were excluded from Clarity AD for the presence of >4 microhemorrhages and additional findings suggestive of CAA (prior cerebral hemorrhage >1 cm in greatest diameter, superficial siderosis, vasogenic edema) or other lesions (aneurysm, vascular malformation) that could potentially increase the risk of ICH.

Concomitant Antithrombotic or Thrombolytic Medication
In Clarity AD, baseline use of antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) was allowed if the patient was on a stable dose. Most exposures were to aspirin. Antithrombotic medications did not increase the risk of ARIA with LEQEMBI. The incidence of ICH: 0.9% in patients taking LEQEMBI with a concomitant antithrombotic medication vs 0.6% with no antithrombotic and 2.5% in patients taking LEQEMBI with an anticoagulant alone or with antiplatelet medication such as aspirin vs none in patients receiving placebo.

Fatal cerebral hemorrhage has occurred in 1 patient taking an anti-amyloid monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use of a thrombolytic agent.

Additional caution should be exercised when considering the administration of antithrombotics or a thrombolytic agent (e.g., tissue plasminogen activator) to a patient already being treated with LEQEMBI. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with LEQEMBI.

Caution should be exercised when considering the use of LEQEMBI in patients with factors that indicate an increased risk for ICH and, in particular, patients who need to be on anticoagulant therapy or patients with findings on MRI that are suggestive of CAA.

Radiographic Severity With LEQEMBI
Most ARIA-E radiographic events occurred within the first 7 doses, although ARIA can occur at any time, and patients can have >1 episode. Maximum radiographic severity of ARIA-E with LEQEMBI was mild in 4%, moderate in 7%, and severe in 1% of patients. Resolution on MRI occurred in 52% of ARIA-E patients by 12 weeks, 81% by 17 weeks, and 100% overall after detection. Maximum radiographic severity of ARIA-H microhemorrhage with LEQEMBI was mild in 9%, moderate in 2%, and severe in 3% of patients; superficial siderosis was mild in 4%, moderate in 1%, and severe in 0.4% of patients. With LEQEMBI, the rate of severe radiographic ARIA-E was highest in ApoE ε4 homozygotes (5%) vs heterozygotes (0.4%) or noncarriers (0%). With LEQEMBI, the rate of severe radiographic ARIA-H was highest in ApoE ε4 homozygotes (13.5%) vs heterozygotes (2.1%) or noncarriers (1.1%).

Monitoring and Dose Management Guidelines
Baseline brain MRI and periodic monitoring with MRI are recommended. Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment. Depending on ARIA-E and ARIA-H clinical symptoms and radiographic severity, use clinical judgment when considering whether to continue dosing or to temporarily or permanently discontinue LEQEMBI. If a patient experiences ARIA symptoms, clinical evaluation should be performed, including MRI if indicated. If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment.

HYPERSENSITIVITY REACTIONS

Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred with LEQEMBI. Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction and initiate appropriate therapy.

INFUSION-RELATED REACTIONS (IRRs)

IRRs were observed—LEQEMBI: 26%; placebo: 7%—and most cases with LEQEMBI (75%) occurred with the first infusion. IRRs were mostly mild (69%) or moderate (28%). Symptoms included fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation.

IRRs can occur during or after the completion of infusion. In the event of an IRR during the infusion, the infusion rate may be reduced or discontinued, and appropriate therapy initiated as clinically indicated. Consider prophylactic treatment prior to future infusions with antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, or corticosteroids.

ADVERSE REACTIONS

The most common adverse reactions reported in ≥5% with LEQEMBI infusion every 2 weeks and ≥2% higher than placebo were IRRs (LEQEMBI: 26%; placebo: 7%), ARIA-H (LEQEMBI: 14%; placebo: 8%), ARIA-E (LEQEMBI: 13%; placebo: 2%), headache (LEQEMBI: 11%; placebo: 8%), superficial siderosis of central nervous system (LEQEMBI: 6%; placebo: 3%), rash (LEQEMBI: 6%; placebo: 4%), and nausea/vomiting (LEQEMBI: 6%; placebo: 4%)Safety profile of LEQEMBI IQLIK for maintenance treatment was similar to LEQEMBI infusion. Patients who received LEQEMBI IQLIK experienced localized and systemic (less frequent) injection-related reactions (mild to moderate in severity) LEQEMBI (lecanemab-irmb) is available:

Intravenous infusion: 100 mg/mLSubcutaneous injection: 200 mg/mL Please see full Prescribing Information for LEQEMBI, including Boxed WARNING.

MEDIA CONTACTS Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120Eisai Europe, Ltd.
EMEA Communications Department
+44 (0) 797 487 9419

[email protected] Inc. (U.S.)
Libby Holman
+1-201-753-1945

[email protected] Inc.
Madeleine Shin
+1-781-464-3260
[email protected] INVESTOR CONTACTS Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122Biogen Inc.
Tim Power
+ 1-781-464-2442
[email protected] Notes to Editors

1.   About lecanemab (generic name, brand name: LEQEMBI®)

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Lecanemab has been approved in 50 countries and is under regulatory review in 10 countries. The supplemental Biologics License Application (sBLA) for intravenous (IV) maintenance dosing of the treatment was approved in the U.S.in January 2025 and China in September 2025, and applications have been filed in 5 countries and regions.

LEQEMBI's approvals in these countries was based on Phase 3 data from Eisai's, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with lecanemab reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001). In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted a statistically significant benefit of 37% compared to placebo. The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADL score was −3.5 in the lecanemab group and −5.5 in the placebo group (difference, 2.0; 95% CI, 1.2 to 2.8; P<0.001). The ADCS MCI-ADL assesses the ability of patients to function independently, including being able to dress, feed themselves and participate in community activities. The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.

The subcutaneous maintenance dosing approval is based on LEQEMBI subcutaneous (SC) sub-studies of the Phase 3 Clarity AD open-label extension (OLE) trial in individuals with early AD which evaluated a range of subcutaneous doses. Data shows that transitioning to the weekly LEQEMBI IQLIKTM autoinjector after 18 months of the initiation dose (10 mg/kg IV every two weeks) maintains clinical and biomarker benefits comparable to continued IV dosing. The safety of LEQEMBI IQLIK autoinjector was studied in over 600 patients at a range of doses as part of the Clarity AD OLE. Across all subcutaneous doses, the safety profile was similar to that of the IV maintenance treatment with one key difference: systemic reactions were much less common with subcutaneous dosing—less than 1% compared to approximately 26% with IV infusions. ARIA rates in patients who received a weekly 360 mg subcutaneous maintenance dose were similar to ARIA rates reported in patients who continued with the IV dose after 18 months and are similar to the background rates of ARIA in patients without treatment.

Since July 2020, the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai, and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

2.   About the Collaboration between Eisai and Biogen for AD

Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.

3.   About the Collaboration between Eisai and BioArctic for AD

Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.

4.   About Eisai Co., Ltd.

Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.

5.   About Biogen

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for lecanemab-irmb (LEQEMBI IQLIK); the potential to streamline the Alzheimer's disease treatment pathway; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

News Summary:

NVIDIA founder and CEO Jensen Huang delivers DGX Spark to Elon Musk at SpaceX.This week, NVIDIA and its partners are shipping DGX Spark, the world’s smallest AI supercomputer, delivering NVIDIA’s AI stack in a compact desktop form factor.Acer, ASUS, Dell Technologies, GIGABYTE, HPI, Lenovo and MSI debut DGX Spark systems, expanding access to powerful AI computing.Built on the NVIDIA Grace Blackwell architecture, DGX Spark integrates NVIDIA GPUs, CPUs, networking, CUDA libraries and NVIDIA AI software, accelerating agentic and physical AI development. SANTA CLARA, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- NVIDIA today announced it will start shipping NVIDIA DGX Spark™, the world’s smallest AI supercomputer.

AI workloads are quickly outgrowing the memory and software capabilities of the PCs, workstations and laptops millions of developers rely on today — forcing teams to shift work to the cloud or local data centers.

As a new class of computer, DGX Spark delivers a petaflop of AI performance and 128GB of unified memory in a compact desktop form factor, giving developers the power to run inference on AI models with up to 200 billion parameters and fine-tune models of up to 70 billion parameters locally. In addition, DGX Spark lets developers create AI agents and run advanced software stacks locally.

“In 2016, we built DGX-1 to give AI researchers their own supercomputer. I hand-delivered the first system to Elon at a small startup called OpenAI — and from it came ChatGPT, kickstarting the AI revolution,” said Jensen Huang, founder and CEO of NVIDIA. “DGX-1 launched the era of AI supercomputers and unlocked the scaling laws that drive modern AI. With DGX Spark, we return to that mission — placing an AI computer in the hands of every developer to ignite the next wave of breakthroughs.”

DGX Spark brings together the full NVIDIA AI platform — including GPUs, CPUs, networking, CUDA® libraries and the NVIDIA AI software stack — into a system small enough for a lab or an office, yet powerful enough to accelerate agentic and physical AI development. By combining breakthrough performance with the reach of the NVIDIA ecosystem, DGX Spark transforms the desktop into an AI development platform.

DGX Spark systems deliver up to 1 petaflop of AI performance, accelerated by a NVIDIA GB10 Grace Blackwell Superchip, NVIDIA ConnectX®-7 200 Gb/s networking and NVIDIA NVLink™-C2C technology, providing 5x the bandwidth of fifth-generation PCIe with 128GB of CPU-GPU coherent memory.

The NVIDIA AI software stack is preinstalled to enable developers to start working on AI projects out of the box. With DGX Spark, developers can access NVIDIA AI ecosystem tools including models, libraries, and NVIDIA NIM™ microservices, enabling local workflows such as customizing Black Forest Labs’ FLUX.1 models to refine image generation, creating a vision search and summarization agent using the NVIDIA Cosmos™ Reason vision language model, or building an AI chatbot using Qwen3 that is optimized for DGX Spark.

To celebrate DGX Spark shipping worldwide, Huang hand-delivered one of the first units of DGX Spark to Elon Musk, chief engineer at SpaceX, today in Starbase, Texas. The exchange was a connection to the supercomputer’s origins, as Musk was among the team that received the first NVIDIA DGX™-1 supercomputer from Huang in 2016.

Other early recipients of DGX Spark, including Anaconda, Cadence, ComfyUI, Docker, Google, Hugging Face, JetBrains, LM Studio, Meta, Microsoft, Ollama and Roboflow, are testing, validating and optimizing their tools, software and models for DGX Spark.

Research organizations around the world, including the NYU Global Frontier Lab, previewed DGX Spark to boost their AI development.

“DGX Spark allows us to access peta-scale computing on our desktop,” said Kyunghyun Cho, professor of computer and data science at the NYU Global Frontier Lab. “This new way to conduct AI research and development enables us to rapidly prototype and experiment with advanced AI algorithms and models — even for privacy- and security-sensitive applications, such as healthcare.”

NVIDIA DGX Spark Now Shipping
Starting Wednesday, Oct. 15, DGX Spark can be ordered on NVIDIA.com. Partner systems will be available from Acer, ASUS, Dell Technologies, GIGABYTE, HP, Lenovo, MSI as well as Micro Center stores in the U.S., and from NVIDIA channel partners worldwide.

About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:
Alex Shapiro
Public Relations
NVIDIA Corporation
+1-415-608-5044
[email protected] 

Certain statements in this press release including, but not limited to, statements as to: with DGX Spark, NVIDIA placing an AI computer in the hands of every developer to ignite the next wave of breakthroughs; the benefits, impact, performance, and availability of NVIDIA’s products, services, and technologies; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing product and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

© 2025 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, ConnectX, CUDA, DGX, NVIDIA Cosmos, NVIDIA NIM and NVLink are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other NVIDIA trademarks and service marks not listed herein are also the property of NVIDIA Corporation. All rights reserved. All other company and product names are trademarks or registered trademarks of their respective owners. Features, pricing, availability and specifications are subject to change without notice.

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/ee138c12-fd60-431a-9b43-c6fb1a34287c

https://www.globenewswire.com/NewsRoom/AttachmentNg/a6e9e492-6a02-47d9-9042-856c567fd7c9

NVIDIA DGX Spark
As a new class of computer, DGX Spark delivers a petaflop of AI performance and 128GB of unified mem...

Asia-Pacific markets were set to open lower Tuesday, breaking ranks with gains on Wall Street after U.S. President Donald Trump softened his stance on China.

Following a slew of tit-for-tat trade restrictions and heated exchanges, Trump said "Don't worry about China, it will all be fine!" in a Truth Social post Monday.

China has slapped fees on U.S. ships for docking at its ports, in retaliation for similar charges imposed by Washington on Chinese ships. Both fees are scheduled to kick in today.

Japan's benchmark Nikkei 225 index was set for a lower open, with its futures contract in Chicago trading at 47,235, and its counterpart in Osaka at 46,980, against the index's Monday close of 48,088.8.

Australia's ASX/S&P 200 was down 0.25%.

Hong Kong's Hang Seng Index was set to open lower, with its futures contract trading at 25,794, against the index's previous close of 25,889.48.

U.S. equity futures were little changed in early Asian hours. On Monday stateside, the key benchmarks recovered a significant chunk of their losses suffered last week after Trump's Truth Social post.

Overnight, the Dow Jones Industrial Average closed higher by 587.98 points, or 1.29%, to 46,067.58, which equates to 67% of its Friday loss. The S&P 500 rose 1.56% to finish at 6,654.72, retracing 56% of its prior decline. The Nasdaq Composite popped 2.21% to settle at 22,694.61 as beaten-down technology stocks led the bounce.

— CNBC's Alex Harring, Sarah Min and Fred Imbert contributed to this report.

A fire knocked a crucial aluminum supplier offline until next year. Moneymaking F-150 trucks are vulnerable.

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued materially misleading business information to the investing public.

So What: If you purchased Soleno Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On August 15, 2025, Investing.com published a story entitled "Soleno Therapeutics stock falls after Scorpion Capital short report." The article stated that Soleno Therapeutics stock had fallen "following a short report from Scorpion Capital that raised serious concerns about the company's recently approved Prader-Willi syndrome treatment, VYKAT XR." It further stated that the Scorpion Capital report "highlighted personal safety issues," and that it "suggested the drug may be at risk of being withdrawn from the market or facing a significant decline in new prescriptions."

On this news, Soleno Therapeutics' stock fell 7.4% on August 15, 2025. It fell a further 4.9% on the next trading day.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Honeywell logo is seen in this illustration taken July 26, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

Oct 13 (Reuters) - Aerospace supplier Honeywell

(HON.O), opens new tab said on Monday it expects record deliveries of new business jets over the next decade, providing the latest sign that demand for private air travel, which surged during the COVID-19 pandemic, is holding up.

Affluent travelers, who avoided scheduled flights in 2020, helped private flying recover earlier than the commercial airlines' business, but there were doubts whether they would stick with private air travel once the pandemic was over.

Sign up here.

A report by the U.S. maker of avionics and business jet engines, forecasts private plane deliveries at a higher level than before the pandemic, with demand for planes resilient despite a U.S.-led trade war and geopolitical tensions.

Honeywell predicts global deliveries of 8,500 new business jets with a projected value of $283 billion – the highest in the report’s 34-year history – over the next decade. The report comes ahead of the world's largest business jet show, which starts on Tuesday in Las Vegas.

"More people are flying in business aviation than pre-COVID," said Ben Driggs, chief commercial and strategy officer at Honeywell Aerospace in an interview.

"Those hours have continued to increase at a much higher level since 2019, so it appears like people are really staying with business aviation."

Demand has driven up shares of Canadian planemaker Bombardier

(BBDb.TO), opens new tab which is set to start deliveries of its Global 8000 business jet, even as U.S. rival Gulfstream Aerospace launches a replacement to its super-midsized G280.

New business jet deliveries are expected to grow 5%, while 91% of operators expect to fly more than this year.

Reporting By Allison Lampert in Montreal
Editing by Tomasz Janowski

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in MO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Alaska Air Group (ALK - Free Report) closed at $48.27 in the latest trading session, marking a +2.22% move from the prior day. This change outpaced the S&P 500's 1.56% gain on the day. At the same time, the Dow added 1.29%, and the tech-heavy Nasdaq gained 2.21%.

The stock of airline has fallen by 25.49% in the past month, lagging the Transportation sector's loss of 1.12% and the S&P 500's gain of 0.41%.

Market participants will be closely following the financial results of Alaska Air Group in its upcoming release. The company plans to announce its earnings on October 23, 2025. On that day, Alaska Air Group is projected to report earnings of $1.11 per share, which would represent a year-over-year decline of 50.67%. At the same time, our most recent consensus estimate is projecting a revenue of $3.75 billion, reflecting a 22.21% rise from the equivalent quarter last year.

For the full year, the Zacks Consensus Estimates project earnings of $3.02 per share and a revenue of $14.28 billion, demonstrating changes of -37.99% and +21.69%, respectively, from the preceding year.

Investors should also note any recent changes to analyst estimates for Alaska Air Group. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 10.8% lower. Alaska Air Group is currently sporting a Zacks Rank of #5 (Strong Sell).

From a valuation perspective, Alaska Air Group is currently exchanging hands at a Forward P/E ratio of 15.65. This valuation marks a premium compared to its industry average Forward P/E of 9.77.

One should further note that ALK currently holds a PEG ratio of 0.73. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Transportation - Airline stocks are, on average, holding a PEG ratio of 0.73 based on yesterday's closing prices.

The Transportation - Airline industry is part of the Transportation sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 37% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

In the latest trading session, Archer Daniels Midland (ADM - Free Report) closed at $61.64, marking a +1.31% move from the previous day. The stock's change was less than the S&P 500's daily gain of 1.56%. On the other hand, the Dow registered a gain of 1.29%, and the technology-centric Nasdaq increased by 2.21%.

Shares of the agribusiness giant witnessed a loss of 1.19% over the previous month, beating the performance of the Consumer Staples sector with its loss of 2.88%, and underperforming the S&P 500's gain of 0.41%.

Investors will be eagerly watching for the performance of Archer Daniels Midland in its upcoming earnings disclosure. The company is predicted to post an EPS of $0.87, indicating a 20.18% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $19.8 billion, down 0.69% from the year-ago period.

ADM's full-year Zacks Consensus Estimates are calling for earnings of $3.99 per share and revenue of $83.58 billion. These results would represent year-over-year changes of -15.82% and -2.28%, respectively.

Investors should also pay attention to any latest changes in analyst estimates for Archer Daniels Midland. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Archer Daniels Midland is currently a Zacks Rank #3 (Hold).

In terms of valuation, Archer Daniels Midland is presently being traded at a Forward P/E ratio of 15.23. For comparison, its industry has an average Forward P/E of 15.23, which means Archer Daniels Midland is trading at no noticeable deviation to the group.

It's also important to note that ADM currently trades at a PEG ratio of 3.24. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the Agriculture - Operations industry stood at 1.71 at the close of the market yesterday.

The Agriculture - Operations industry is part of the Consumer Staples sector. Currently, this industry holds a Zacks Industry Rank of 151, positioning it in the bottom 39% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of MSCI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of V.F. Corporation (NYSE: VFC) between October 30, 2023 and May 20, 2025, both dates inclusive (the “Class Period”), of the important November 12, 2025 lead plaintiff deadline.

SO WHAT: If you purchased V.F. Corporation securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the V.F. Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=44811 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants disseminated materially false and misleading statements and/or concealed material adverse facts concerning the true state of V.F. Corporation’s turnaround plans. Specifically, defendants provided investors with material information concerning V.F. Corporation’s turnaround plan (“Reinvent”), which in part focused on efforts to return the Vans brand to positive growth. The lawsuit alleges that defendants concealed that additional significant reset actions would be necessary to return the Vans brand to growth, and would result in significant setbacks to Vans’ revenue growth trajectory. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the V.F. Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=44811 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Dow Inc. (NYSE: DOW) between January 30, 2025 and July 23, 2025, both dates inclusive (the “Class Period”), of the important October 28, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Dow securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Dow class action, go to https://rosenlegal.com/submit-form/?case_id=44352 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Dow’s ability to mitigate macroeconomic and tariff-related headwinds, as well as to maintain the financial flexibility needed to support its lucrative dividend, was overstated; (2) the true scope and severity of the foregoing headwinds’ negative impacts on Dow’s business and financial condition was understated, particularly with respect to competitive and pricing pressures, softening global sales and demand for Dow’s products, and an oversupply of products in Dow’s global markets; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Dow class action, go to https://rosenlegal.com/submit-form/?case_id=44352 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Griffon (GFF - Free Report) closed at $72.91 in the latest trading session, marking a -1% move from the prior day. This change lagged the S&P 500's daily gain of 1.56%. Elsewhere, the Dow gained 1.29%, while the tech-heavy Nasdaq added 2.21%.

Shares of the garage door and building products maker have depreciated by 4.97% over the course of the past month, outperforming the Conglomerates sector's loss of 12.34%, and lagging the S&P 500's gain of 0.41%.

The investment community will be closely monitoring the performance of Griffon in its forthcoming earnings report. The company's upcoming EPS is projected at $1.56, signifying a 6.12% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $629.69 million, down 4.55% from the year-ago period.

GFF's full-year Zacks Consensus Estimates are calling for earnings of $5.67 per share and revenue of $2.49 billion. These results would represent year-over-year changes of +10.74% and 0%, respectively.

Investors should also take note of any recent adjustments to analyst estimates for Griffon. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.78% decrease. Griffon currently has a Zacks Rank of #3 (Hold).

Investors should also note Griffon's current valuation metrics, including its Forward P/E ratio of 11.64. For comparison, its industry has an average Forward P/E of 17.82, which means Griffon is trading at a discount to the group.

It is also worth noting that GFF currently has a PEG ratio of 1. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Diversified Operations industry was having an average PEG ratio of 1.71.

The Diversified Operations industry is part of the Conglomerates sector. This group has a Zacks Industry Rank of 93, putting it in the top 38% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Halliburton (HAL - Free Report) ended the recent trading session at $22.50, demonstrating a +2.41% change from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 1.56%. Elsewhere, the Dow saw an upswing of 1.29%, while the tech-heavy Nasdaq appreciated by 2.21%.

Heading into today, shares of the provider of drilling services to oil and gas operators had lost 1.17% over the past month, outpacing the Oils-Energy sector's loss of 2.93% and lagging the S&P 500's gain of 0.41%.

The upcoming earnings release of Halliburton will be of great interest to investors. The company's earnings report is expected on October 21, 2025. The company's earnings per share (EPS) are projected to be $0.5, reflecting a 31.51% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $5.39 billion, indicating a 5.31% decrease compared to the same quarter of the previous year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.11 per share and a revenue of $21.43 billion, signifying shifts of -29.43% and -6.6%, respectively, from the last year.

Investors should also take note of any recent adjustments to analyst estimates for Halliburton. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.54% downward. As of now, Halliburton holds a Zacks Rank of #4 (Sell).

In the context of valuation, Halliburton is at present trading with a Forward P/E ratio of 10.43. For comparison, its industry has an average Forward P/E of 15.27, which means Halliburton is trading at a discount to the group.

The Oil and Gas - Field Services industry is part of the Oils-Energy sector. Currently, this industry holds a Zacks Industry Rank of 93, positioning it in the top 38% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Vita Coco Company, Inc. (COCO - Free Report) closed at $39.81 in the latest trading session, marking a -4.76% move from the prior day. This change lagged the S&P 500's daily gain of 1.56%. Elsewhere, the Dow gained 1.29%, while the tech-heavy Nasdaq added 2.21%.

Prior to today's trading, shares of the company had gained 5.64% outpaced the Consumer Staples sector's loss of 2.88% and the S&P 500's gain of 0.41%.

The upcoming earnings release of Vita Coco Company, Inc. will be of great interest to investors. On that day, Vita Coco Company, Inc. is projected to report earnings of $0.32 per share, which would represent no growth from the year-ago period. Meanwhile, our latest consensus estimate is calling for revenue of $158.78 million, up 19.46% from the prior-year quarter.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.15 per share and a revenue of $585.18 million, signifying shifts of +7.48% and +13.4%, respectively, from the last year.

Any recent changes to analyst estimates for Vita Coco Company, Inc. should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.52% decrease. Vita Coco Company, Inc. currently has a Zacks Rank of #5 (Strong Sell).

In the context of valuation, Vita Coco Company, Inc. is at present trading with a Forward P/E ratio of 36.35. This valuation marks a premium compared to its industry average Forward P/E of 18.22.

Investors should also note that COCO has a PEG ratio of 2.72 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Beverages - Soft drinks industry held an average PEG ratio of 2.47.

The Beverages - Soft drinks industry is part of the Consumer Staples sector. This group has a Zacks Industry Rank of 208, putting it in the bottom 16% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

In the latest trading session, Lucid Group (LCID - Free Report) closed at $21.39, marking a +1.95% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 1.56%. At the same time, the Dow added 1.29%, and the tech-heavy Nasdaq gained 2.21%.

Coming into today, shares of the an electric vehicle automaker had gained 8.85% in the past month. In that same time, the Auto-Tires-Trucks sector gained 9.55%, while the S&P 500 gained 0.41%.

Investors will be eagerly watching for the performance of Lucid Group in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 5, 2025. The company is predicted to post an EPS of -$2.33, indicating a 43.17% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $325.59 million, up 62.76% from the year-ago period.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$8.89 per share and a revenue of $1.26 billion, indicating changes of +28.88% and +55.98%, respectively, from the former year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Lucid Group. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Right now, Lucid Group possesses a Zacks Rank of #3 (Hold).

The Automotive - Domestic industry is part of the Auto-Tires-Trucks sector. This industry currently has a Zacks Industry Rank of 195, which puts it in the bottom 22% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow LCID in the coming trading sessions, be sure to utilize Zacks.com.

Adecoagro (AGRO - Free Report) closed the most recent trading day at $7.68, moving +1.72% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 1.56%. Meanwhile, the Dow experienced a rise of 1.29%, and the technology-dominated Nasdaq saw an increase of 2.21%.

Heading into today, shares of the producer of agricultural products and renewable energy had lost 6.21% over the past month, lagging the Consumer Staples sector's loss of 2.88% and the S&P 500's gain of 0.41%.

Investors will be eagerly watching for the performance of Adecoagro in its upcoming earnings disclosure.

AGRO's full-year Zacks Consensus Estimates are calling for earnings of $0.35 per share and revenue of $1.35 billion. These results would represent year-over-year changes of -82.67% and -11.27%, respectively.

Investors should also take note of any recent adjustments to analyst estimates for Adecoagro. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 11.39% lower. Adecoagro currently has a Zacks Rank of #4 (Sell).

From a valuation perspective, Adecoagro is currently exchanging hands at a Forward P/E ratio of 21.57. This valuation marks a premium compared to its industry average Forward P/E of 15.23.

The Agriculture - Operations industry is part of the Consumer Staples sector. Currently, this industry holds a Zacks Industry Rank of 151, positioning it in the bottom 39% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Superior Group (SGC - Free Report) closed at $10.07 in the latest trading session, marking a -1.76% move from the prior day. This change lagged the S&P 500's daily gain of 1.56%. Meanwhile, the Dow experienced a rise of 1.29%, and the technology-dominated Nasdaq saw an increase of 2.21%.

Shares of the uniform maker have depreciated by 13.06% over the course of the past month, underperforming the Consumer Discretionary sector's loss of 5.13%, and the S&P 500's gain of 0.41%.

Investors will be eagerly watching for the performance of Superior Group in its upcoming earnings disclosure. On that day, Superior Group is projected to report earnings of $0.22 per share, which would represent a year-over-year decline of 33.33%. Meanwhile, our latest consensus estimate is calling for revenue of $144.42 million, down 3.52% from the prior-year quarter.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.47 per share and revenue of $571.54 million, indicating changes of -35.62% and +1.04%, respectively, compared to the previous year.

Investors should also pay attention to any latest changes in analyst estimates for Superior Group. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Superior Group is holding a Zacks Rank of #3 (Hold) right now.

Looking at valuation, Superior Group is presently trading at a Forward P/E ratio of 21.66. For comparison, its industry has an average Forward P/E of 14.17, which means Superior Group is trading at a premium to the group.

It's also important to note that SGC currently trades at a PEG ratio of 2.17. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Textile - Apparel industry had an average PEG ratio of 2.17.

The Textile - Apparel industry is part of the Consumer Discretionary sector. This industry currently has a Zacks Industry Rank of 212, which puts it in the bottom 15% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

In the latest close session, PagSeguro Digital Ltd. (PAGS - Free Report) was up +1.14% at $8.85. This move lagged the S&P 500's daily gain of 1.56%. Meanwhile, the Dow experienced a rise of 1.29%, and the technology-dominated Nasdaq saw an increase of 2.21%.

Heading into today, shares of the company had lost 8.28% over the past month, lagging the Business Services sector's loss of 3.52% and the S&P 500's gain of 0.41%.

Analysts and investors alike will be keeping a close eye on the performance of PagSeguro Digital Ltd. in its upcoming earnings disclosure. The company is predicted to post an EPS of $0.35, indicating a 9.38% growth compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $967.82 million, indicating a 11.08% growth compared to the corresponding quarter of the prior year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.38 per share and a revenue of $3.68 billion, signifying shifts of +14.05% and +5.35%, respectively, from the last year.

Investors might also notice recent changes to analyst estimates for PagSeguro Digital Ltd. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 7.17% rise in the Zacks Consensus EPS estimate. PagSeguro Digital Ltd. currently has a Zacks Rank of #1 (Strong Buy).

Looking at valuation, PagSeguro Digital Ltd. is presently trading at a Forward P/E ratio of 6.33. This indicates a discount in contrast to its industry's Forward P/E of 14.35.

One should further note that PAGS currently holds a PEG ratio of 0.44. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Financial Transaction Services industry had an average PEG ratio of 1.15 as trading concluded yesterday.

The Financial Transaction Services industry is part of the Business Services sector. This group has a Zacks Industry Rank of 30, putting it in the top 13% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.